Baetz K~Roberge M, 2004

Pubmed ID 15070751
Title Yeast genome-wide drug-induced haploinsufficiency screen to determine drug mode of action.
Authors Kristin Baetz, Lianne McHardy, Ken Gable, Tamsin Tarling, Delphine Rebérioux, Jenny Bryan, Raymond J Andersen, Teresa Dunn, Phil Hieter, Michel Roberge
Abstract Methods to systematically test drugs against all possible proteins in a cell are needed to identify the targets underlying their therapeutic action and unwanted effects. Here, we show that a genome-wide drug-induced haploinsufficiency screen by using yeast can reveal drug mode of action in yeast and can be used to predict drug mode of action in human cells. We demonstrate that dihydromotuporamine C, a compound in preclinical development that inhibits angiogenesis and metastasis by an unknown mechanism, targets sphingolipid metabolism. The systematic, unbiased and genome-wide nature of this technique makes it attractive as a general approach to identify cellular pathways affected by drugs.
Citation Proc. Natl. Acad. Sci. U.S.A. 2004; 101:4525-30


Download the list of datasets
Paper Phenotype Condition Medium Collection Tested mutants Data Details
Baetz K~Roberge M, 2004 growth (colony size) dihydromotuporamine C [60 uM] YPD het ~5,000 Discrete

Curation history

Tested strains

Oct. 14, 2014 To request.
April 4, 2016 Request sent.
Aug. 16, 2016 Request sent.
May 1, 2017 Request abandoned.


March 28, 2016 Waiting for tested.
May 1, 2017 Ready to load.
May 1, 2017 Loaded.